It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease. To identify additional genetic factors, we analyzed exome sequences in a large cohort of Chinese ALS patients and found a homozygous variant (p.L700P) in PCDHA9 in three unrelated patients. We generated Pcdhα9 mutant mice harboring either orthologous point mutation or deletion mutation. These mice develop progressive spinal motor loss, muscle atrophy, and structural/functional abnormalities of the neuromuscular junction, leading to paralysis and early lethality. TDP-43 pathology is detected in the spinal motor neurons of aged mutant mice. Mechanistically, we demonstrate that Pcdha9 mutation causes aberrant activation of FAK and PYK2 in aging spinal cord, and dramatically reduced NKA-α1 expression in motor neurons. Our single nucleus multi-omics analysis reveals disturbed signaling involved in cell adhesion, ion transport, synapse organization, and neuronal survival in aged mutant mice. Together, our results present PCDHA9 as a potential ALS gene and provide insights into its pathogenesis.
Genetic mutations are found in only 15% of sporadic ALS. Here, authors identify PCDHA9 as a candidate ALS gene and elucidate detailed underlying pathogenesis using mice with Pcdhα9 mutations that develop typical ALS phenotype and hallmark pathology.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Chinese Academy of Sciences, State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Beijing, China (GRID:grid.9227.e) (ISNI:0000000119573309); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419)
2 Capital Medical University, National Clinical Research Center for Geriatric Disease, Department of Neurology, Xuanwu Hospital, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X)
3 Sun Yat-sen University, Department of Neurology, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X)
4 Sichuan University, Department of Neurology, West China Hospital, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581)
5 The First Medical Center, Chinese PLA General Hospital, Department of Neurology, Beijing, China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)
6 Fujian Medical University Union Hospital, Department of Neurology, Fuzhou, China (GRID:grid.411176.4) (ISNI:0000 0004 1758 0478)
7 Shenzhen Clabee Biotechnology Incorporation, Shenzhen, China (GRID:grid.24696.3f)
8 National Center for Children’s Health, Shanghai Key Laboratory of Birth Defects, Division of Neonatology, Children’s Hospital of Fudan University, Shanghai, China (GRID:grid.411333.7) (ISNI:0000 0004 0407 2968)